US is key---innovation profits fund research abroad
Tomas J. Philipson 10, Ph.D., is the Daniel Levin Professor of Public Policy at The University of Chicago and The Chairman of Project FDA of The Manhattan Institute. 4/23/10, “We Can't Lose Our Global Leadership In Medical Innovation” http://www.foxnews.com/opinion/2010/04/23/tomas-philipson-obamacare-health-care-europe-medical-innovation.html
Has Europe found some new way to have their cake and eat it too – enjoying both lower costs and high levels of innovation?
In a word, no. Solidarity is cheap in Europe, but only because it is expensive in the U.S. The United States generates the lion’s share of global profits for medical innovators, because so far U.S. policymakers have rejected explicit price controls on private markets. For example, more than half the world’s sales of drugs occur in the U.S., even though the U.S. represents only about one-fifth of the world economy. Profits generated in the United States allow innovators across the world to fund the expensive R&D efforts that are critical for bringing innovative new medicines to market.
Countries like the United Kingdom, with just 3% of world drug sales, face very different incentives. In fact, it is in their self-interest to provide solidarity through government-controlled prices, because such a policy does not significantly affect the flow of new medicines into Britain. As long as the U.S. underwrites world innovation, E.U. member countries can “free ride” on the new flow of treatments largely paid for by American free-market policies.